Communiqués Brii Biosciences Limited

Actions

2137

KYG1645A1094

Recherche biotechnologique et médicale

Marché Fermé - Hong Kong S.E. 10:08:27 30/09/2026			Varia. 5j.	Varia. 1 janv.
0,8650 ^HKD	+0,58%		-2,26%	-38,65%

24/08	Brii Biosciences Limited (SEHK:2137) lance un programme de rachat d’actions portant sur 72 185 205 titres, soit 10 % de son capital émis, en vertu de l’autorisation approuvée le 16 juin 2026.	CI
21/08	Brii Biosciences Limited publie ses résultats pour le semestre clos le 30 juin 2026	CI

Communiqués

21/08	Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results	PR
06/07	Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B	AQ
27/05	Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV	PR
19/03	Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results	PR
07/11	Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine	PR
21/08/25	Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results	PR
04/07/25	Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China	PR
08/05/25	Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss	PR
30/03/25	Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification	PR
02/01/25	Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study	AQ
31/12/24	Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study	PR
20/11/24	Brii Bio Delivers First Head-to-Head Comparison of siRNA and PEG-IFN Combination versus PEG-IFN Alone at AASLD's The Liver Meeting 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA	AQ
07/06/24	Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024	PR
14/05/24	Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies	PR
05/03/24	Brii Biosciences Announces Agreements To Acquire VBI Vaccines' IP Rights In BRII-179	AQ
14/02/24	Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies	PR
03/01/24	Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer	PR
06/09/23	Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B	PR
22/08/23	Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results	PR
06/07/23	Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure	PR
06/07/23	Brii Biosciences Provides Latest Clinical Development and Corporate Updates	PR
26/06/23	Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693	PR
25/06/23	Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023	PR
01/06/23	Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders	PR
28/04/23	Brii Bio Publishes 2022 Environmental, Social and Governance Report	PR